



- (51) **International Patent Classification:**
C07K 16/24 (2006.01) *C07K 16/28* (2006.01)
- (21) **International Application Number:**
PCT/EP2022/057554
- (22) **International Filing Date:**
22 March 2022 (22.03.2022)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
63/164,991 23 March 2021 (23.03.2021) US
- (71) **Applicant:** GLYCOERA AG [CH/CH]; Grabenstr., 3, 8952 Schlieren (CH).
- (72) **Inventors:** FARIDMOAYER, Amirreza; Grabenstr., 3, 8952 Schlieren (CH). FOLLADOR, Rainer; Grabenstr., 3, 8952 Schlieren (CH). MALLY, Manuela; Grabenstr., 3, 8952 Schlieren (CH). BACK, Jonathan Alber; Grabenstr., 3, 8952 Schlieren (CH).
- (74) **Agent:** JONES DAY; Prinzregentenstraße 11, 80538 München (DE).

(81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, IT, JM, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.

(84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

(54) **Title:** MANNOSE 3 GLYCAN-MEDIATED PROTEIN DEGRADATION




FIG. 1

(57) **Abstract:** The present disclosure provides bifunctional binding proteins for mannose 3 glycan-mediated degradation. Such glycan modifications will improve current treatments and allow a better quality of life for patients. Accordingly, such bifunctional binding proteins are useful for treating and preventing various diseases.

[Continued on next page]

Published:

- *with international search report (Art. 21(3))*
- *before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))*